longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Supernus Pharma

SUPN

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is -23.59, within the reasonable range, cheaper than 78.89% of the time in the past 5 years, and the industry ranks 206/256, the industry Median -1.38.

-23.59xP/E
$44.60Stock price
$-1.89Earnings per share
-23.59xP/E
Stock price$44.60Earnings per share$-1.89

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
32.30x
Typical range
-25.53x–48.66x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0295887116

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
P/E ratio
Name/Symbol
TAKUSTakeda Pharmaceutical Company
-57.18x149.86%$59.71B
BAYRYUSBayer
-28.16x--$56.82B
BAYZFUSBayer Aktiengesellschaft
-28.05x--$56.59B
VTRSUSViatris
-51.10x107.75%$20.98B
ELANUSElanco Animal Health
-56.36x129.36%$11.22B
AXSMUSAxsome Therap
-52.99x26.69%$10.16B
VREOFUSVIREO GROWTH INC
-142.24x--$9.55B
CURLFUSCuraleaf Holdings, Inc.
-159.93x--$8.32B
BLTEUSBelite Bio
-65.28x29.87%$6.68B
DFTXUSDefinium Therapeutics
-14.59x53.61%$5.16B
MANEUSVeraDermics
-46.07x97.44%$4.80B
EWTXUSEdgewise Therapeutics
-21.91x137.29%$4.32B
AMLXUSAmylyx Pharmaceuticals
-24.63x1.76%$3.75B
ELVNUSEnliven Therapeutics
-31.83x1.17%$3.37B
TARSUSTarsus Pharmaceuticals
-72.52x205.82%$3.37B
RGCUSRegencell Bioscience
-435.82x--$3.07B
MBXUSMBX Biosciences
-26.57x30.54%$2.77B
SUPNUSSupernus Pharma
-23.59x70.59%$2.59B
GPCRUSStructure Therapeutics
-11.64x102.05%$2.50B
TRLVUSTrulieve Cannabis
-5.02x198.82%$2.38B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.